HRP20110179T1 - Kimerni adenovirusi za uporabu u liječenju raka - Google Patents
Kimerni adenovirusi za uporabu u liječenju raka Download PDFInfo
- Publication number
- HRP20110179T1 HRP20110179T1 HR20110179T HRP20110179T HRP20110179T1 HR P20110179 T1 HRP20110179 T1 HR P20110179T1 HR 20110179 T HR20110179 T HR 20110179T HR P20110179 T HRP20110179 T HR P20110179T HR P20110179 T1 HRP20110179 T1 HR P20110179T1
- Authority
- HR
- Croatia
- Prior art keywords
- adenovirus
- cell
- region
- nucleic acid
- acid sequence
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract 49
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 201000011510 cancer Diseases 0.000 title claims 4
- 210000004881 tumor cell Anatomy 0.000 claims abstract 15
- 150000007523 nucleic acids Chemical group 0.000 claims abstract 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 8
- 230000000174 oncolytic effect Effects 0.000 claims abstract 4
- 231100001274 therapeutic index Toxicity 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 239000006228 supernatant Substances 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 230000010076 replication Effects 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 230000002950 deficient Effects 0.000 claims 3
- 238000003306 harvesting Methods 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 101710094396 Hexon protein Proteins 0.000 claims 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 101710173835 Penton protein Proteins 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 108091005899 fibrous proteins Proteins 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000011024 colonic benign neoplasm Diseases 0.000 claims 1
- 239000012228 culture supernatant Substances 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Rekombinantni kimerni adenovirus koji ima genom koji sadrži E2B područje, naznačen time da navedeno E2B područje sadrži sekvencu nukleinske kiseline koja proizlazi iz prvog adenovirusnog serotipa i sekvencu nukleinske kiseline koja proizlazi iz drugog adenovirusnog serotipa; time da su navedeni prvi i drugi serotipovi svaki odabran iz adenovirusnih podskupina B, C, D, E, ili F i koji su udaljeni jedan od drugoga; itime da je navedeni kimerni adenovirus onkolitički i pokazuje poboljšani terapijski indeks za stanicu tumora. Patent sadrži još 24 patentna zahtjeva.
Claims (25)
1. Rekombinantni kimerni adenovirus koji ima genom koji sadrži E2B područje, naznačen time da navedeno E2B područje sadrži sekvencu nukleinske kiseline koja proizlazi iz prvog adenovirusnog serotipa i sekvencu nukleinske kiseline koja proizlazi iz drugog adenovirusnog serotipa;
time da su navedeni prvi i drugi serotipovi svaki odabran iz adenovirusnih podskupina B, C, D, E, ili F i koji su udaljeni jedan od drugoga; i
time da je navedeni kimerni adenovirus onkolitički i pokazuje poboljšani terapijski indeks za stanicu tumora.
2. Adenovirus prema zahtjevu 1, koji nadalje sadrži područja koja enkodiraju vlaknaste, heksonske i pentonske proteine, naznačen time da nukleinska kiselina koja enkodira vlaknaste, heksonske i pentonske proteine navedenog adenovirusa je iz istog adenovirusnog serotipa.
3. Adenovirus prema zahtjevu 1 ili 2, naznačen time da nadalje sadrži izmijenjeno E3 područje ili nadalje sadrži izmijenjeno E4 područje.
4. Adenovirus prema bilo kojem od zahtjeva 1 do 3, naznačen time da navedena stanica tumora je stanica raka debelog crijeva, dojke, gušterače, pluća, prostate, jajnika, ili hematopoetska stanica tumora.
5. Adenovirus prema zahtjevu 4, naznačen time da navedena stanica tumora je stanica raka debelog crijeva.
6. Adenovirus prema bilo kojem od zahtjeva 1 do 5, naznačen time da nukleotidna sekvenca E2B područja navedenog adenovirusa sadrži SEQ ID NO: 3.
7. Adenovirus prema bilo kojem od zahtjeva 1 do 5, naznačen time da nukleotidna sekvenca navedenog adenovirusa sadrži SEQ ID NO: 1.
8. Rekombinantni kimerni adenovirus koji ima genom koji sadrži E2B područje, naznačen time da navedeno E2B područje sadrži sekvencu nukleinske kiseline koja proizlazi iz prvog adenovirusnog serotipa i sekvencu nukleinske kiseline koja proizlazi iz drugog adenovirusnog serotipa, i
time da navedeni prvi i drugi adenovirusni serotipovi su svaki odabran iz adenovirusnih podskupina B, C, D, E, ili F i koji su udaljeni jedan od drugoga, i
time da navedeni kimerni adenovirus je onkolitički i pokazuje poboljšani terapijski indeks za stanicu tumora, i
time da navedeni kimerni adenovirus je napravljen kao adenovirus s nedostatkom replikacije putem brisanja jednog ili više adenovirusnih područja koja enkodiraju proteine uključene u adenovirusnu replikaciju odabranih iz skupine koja se sastoji od E1, E2, E3 ili E4.
9. Adenovirus s nedostatkom replikacije prema zahtjevu 8, naznačen time da E1 i E3 područja su izbrisana.
10. Adenovirus s nedostatkom replikacije prema zahtjevu 9, naznačen time da nadalje sadrži brisanje E4 područja.
11. Adenovirus prema bilo kojem od prethodnih zahtjeva, koji nadalje sadrži heterologni gen, naznačen time da je navedeni heterologni gen eksprimiran unutar stanice inficirane sa navedenim adenovirusom.
12. Adenovirus prema zahtjevu 11, naznačen time da je navedeni heterologni gen timidin kinaza.
13. Adenovirus prema zahtjevu 11, naznačen time da navedeni heterologni gen enkodira terapeutski protein odabran iz skupine koja se sastoji od citokina i kemokina, antitijela, pro-lijekova koji pretvaraju enzime i imunoregulacijskih proteina.
14. Adenovirus prema bilo kojem od zahtjeva 1 do 13 naznačen time da je za uporabu kod liječenja.
15. Adenovirus prema bilo kojem od zahtjeva 1 do 13 naznačen time da je za uporabu kod liječenja neoplastičnih bolesti ili raka, ili za inhibiciju rasta tumorskih stanica.
16. Postupak za inhibiciju rasta tumorskih stanica, naznačen time da sadrži inficiranje navedene stanice raka in vitro sa adenovirusom prema bilo kojem od zahtjeva 1 do 13.
17. Adenovirus prema zahtjevu 15 ili postupak prema zahtjevu 16, naznačen time da navedena stanica tumora je stanica raka debelog crijeva.
18. Adenovirus ili postupak prema zahtjevu 17, naznačen time da nukleotidna sekvenca navedenog adenovirusa sadrži SEQ ID NO: 1.
19. Adenovirus prema bilo kojem od zahtjeva 1 do 13, naznačen time da je za uporabu za dostavu terapeutskog proteina stanici.
20. Postupak izolacije adenovirusa prema bilo kojem od zahtjeva 1 do 13, naznačen time da navedeni postupak sadrži
a) ujedinjavanje adenovirusnih serotipova koji predstavljaju adenovirusne podskupine B-F, i time stvaraju adenovirusnu mješavinu;
b) prevođenja ujedinjene adenovirusne mješavine iz koraka (a) na aktivno rastuću kulturu tumorskih stanica u dovoljno visokom omjeru čestica po stanici za poticanje rekombinacije između serotipova, ali ne toliko visokim za uzrokovanje prerane smrti stanica;
c) žetve supernatanta iz koraka (b);
d) inficiranja neaktivne kulture tumorskih stanica sa supernatantom dobivenim u koraku (c);
e) žetve stanične kulture supernatanta iz koraka (d) prije bilo kojeg znaka CPE;
f) inficiranja neaktivne kulture tumorskih stanica sa supernatantom dobivenim u koraku (e); i
g) izolacije virusa prema bilo kojem od zahtjeva 1 do 13 iz supernatanta dobivenog u koraku (f) pomoću pročišćavanja plaka.
21. Postupak prema zahtjevu 20, naznačen time da se korak (b) provodi dva puta prije žetve supernatanta u koraku (c).
22. Postupak prema zahtjevu 20, naznačen time da se koraci (e) i (f) ponavljaju do 20 puta prije koraka (g).
23. Postupak prema zahtjevu 20, naznačen time da se drugi krug pročišćavanja plaka provodi nakon koraka (g).
24. Postupak prema zahtjevu 20, naznačen time da stanica tumora je stanica raka debelog crijeva, dojke, gušterače, pluća, prostate, jajnika, ili hematopoetska stanica tumora.
25. Rekombinantni kimerni adenovirus koji ima genom koji sadrži E2B područje, naznačen time da navedeno E2B područje sadrži sekvencu nukleinske kiseline koja proizlazi iz prvog adenovirusnog serotipa i sekvencu nukleinske kiseline koja proizlazi iz drugog adenovirusnog serotipa; i
time da navedeni prvi i drugi adenovirusni serotipovi su svaki odabrani iz adenovirusnih podskupina B, C, D, E, ili F i koji su udaljeni jedan od drugoga; i
time da je navedeni kimerni adenovirus onkolitički i pokazuje poboljšani terapijski indeks za stanicu tumora;
se dobiva postupkom prema bilo kojem od zahtjeva 20 do 24.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57485104P | 2004-05-26 | 2004-05-26 | |
| PCT/US2005/018301 WO2005118825A2 (en) | 2004-05-26 | 2005-05-24 | Chimeric adenoviruses for use in cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110179T1 true HRP20110179T1 (hr) | 2011-04-30 |
Family
ID=35355425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110179T HRP20110179T1 (hr) | 2004-05-26 | 2011-03-11 | Kimerni adenovirusi za uporabu u liječenju raka |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US7510868B2 (hr) |
| EP (1) | EP1749098B1 (hr) |
| JP (1) | JP4787936B2 (hr) |
| KR (1) | KR101169109B1 (hr) |
| CN (3) | CN1997746B (hr) |
| AR (2) | AR049188A1 (hr) |
| AT (1) | ATE491799T1 (hr) |
| AU (1) | AU2005250396B2 (hr) |
| BR (2) | BRPI0510475B8 (hr) |
| CA (2) | CA2836987C (hr) |
| CR (1) | CR8794A (hr) |
| DE (1) | DE602005025340D1 (hr) |
| DK (1) | DK1749098T3 (hr) |
| EC (1) | ECSP067088A (hr) |
| ES (1) | ES2358204T3 (hr) |
| GT (1) | GT200500129A (hr) |
| HK (3) | HK1109421A1 (hr) |
| HR (1) | HRP20110179T1 (hr) |
| IL (2) | IL179098A (hr) |
| MX (1) | MXPA06013570A (hr) |
| MY (1) | MY140829A (hr) |
| NO (1) | NO340708B1 (hr) |
| NZ (1) | NZ551443A (hr) |
| PA (1) | PA8634201A1 (hr) |
| PE (1) | PE20060277A1 (hr) |
| PL (1) | PL1749098T3 (hr) |
| PT (1) | PT1749098E (hr) |
| RU (1) | RU2448157C2 (hr) |
| TW (1) | TWI366603B (hr) |
| UA (1) | UA89957C2 (hr) |
| UY (1) | UY28926A1 (hr) |
| WO (1) | WO2005118825A2 (hr) |
| ZA (1) | ZA200610763B (hr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ551443A (en) * | 2004-05-26 | 2010-01-29 | Schering Ag | Chimeric adenoviruses for use in cancer treatment |
| US20070258952A1 (en) * | 2006-05-04 | 2007-11-08 | Baylor Research Institute | Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA |
| WO2008108890A2 (en) * | 2006-10-18 | 2008-09-12 | University Of Rochester | Conditionally replicating viruses for cancer therapy |
| WO2008060510A2 (en) * | 2006-11-13 | 2008-05-22 | Sangamo Biosciences, Inc. | Zinc finger nuclease for targeting the human glucocorticoid receptor locus |
| WO2008080003A2 (en) * | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
| KR100856310B1 (ko) | 2007-02-28 | 2008-09-03 | 삼성전기주식회사 | 이동통신 단말기 |
| GB201022007D0 (en) | 2010-12-24 | 2011-02-02 | Imp Innovations Ltd | DNA-sensor |
| AU2013231423B2 (en) * | 2012-03-12 | 2018-10-04 | Janssen Vaccines & Prevention B.V. | Batches of recombinant adenovirus with altered terminal ends |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| US9119813B2 (en) | 2012-03-22 | 2015-09-01 | Crucell Holland B.V. | Vaccine against RSV |
| CN104334188B (zh) * | 2012-03-22 | 2016-08-24 | 克鲁塞尔荷兰公司 | 抗rsv疫苗 |
| WO2014131898A1 (en) * | 2013-02-28 | 2014-09-04 | Psioxus Therapuetics Limited | A process for the production of adenovirus |
| EP2971008B1 (en) | 2013-03-14 | 2018-07-25 | Salk Institute for Biological Studies | Oncolytic adenovirus compositions |
| CN112516179A (zh) | 2013-06-14 | 2021-03-19 | 普赛奥克苏斯治疗公司 | 用于b型腺病毒的给药方案及制剂 |
| GB201322851D0 (en) * | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| LT3021859T (lt) * | 2013-10-25 | 2018-06-11 | Psioxus Therapeutics Limited | Onkolitiniai adenovirusai su heterologiniais genais |
| GB2531821A (en) * | 2013-10-25 | 2016-05-04 | Psioxus Therapeutics Ltd | Oncolytic adenoviruses armed with heterologous genes |
| GB201415579D0 (en) | 2014-09-03 | 2014-10-15 | Psioxus Therapeutics Ltd | A process |
| MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| GB201510197D0 (en) | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
| US20170313990A1 (en) | 2014-08-27 | 2017-11-02 | Psioxus Therapeutics Limited | A process for the production of adenovirus |
| EP3391892A1 (en) * | 2015-04-30 | 2018-10-24 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding a b7 protein |
| JP7064437B2 (ja) | 2015-12-17 | 2022-05-10 | サイオクサス セラピューティクス リミテッド | 抗ｔｃｒ複合体抗体又は断片をコードするｂ群アデノウイルス |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| KR102471633B1 (ko) | 2016-02-23 | 2022-11-25 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
| US11273170B2 (en) * | 2016-07-25 | 2022-03-15 | Ascend Biopharmaceuticals Ltd | Methods of treating cancer |
| EP3503918B1 (en) | 2016-08-29 | 2020-09-30 | Psioxus Therapeutics Limited | Adenovirus armed with bispecific t cell engager (bite) |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| CN110062630A (zh) | 2016-12-12 | 2019-07-26 | 萨克生物研究学院 | 肿瘤靶向合成腺病毒及其用途 |
| BR112019024918A2 (pt) | 2017-06-01 | 2020-06-23 | Psioxus Therapeutics Limited | Vírus oncolítico e método |
| EP3679128A1 (en) | 2017-09-05 | 2020-07-15 | GLAdiator Biosciences, Inc. | Method of targeting exosomes |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| KR20210093303A (ko) | 2018-11-21 | 2021-07-27 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 아데노바이러스 및 아데노바이러스의 사용 방법 |
| JP7381604B2 (ja) | 2019-04-29 | 2023-11-15 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 癌を治療するための多価ｐｄ－ｌ１結合化合物 |
| GB201909081D0 (en) | 2019-06-25 | 2019-08-07 | Psioxus Therapeutics Ltd | Method |
| CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
| GB202102049D0 (en) | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| DK0667912T3 (da) | 1993-07-13 | 2008-11-10 | Centelion | Defekte adenovirusvektorer og anvendelse heraf i genterapi |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
| US5877011A (en) * | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| CN1242051A (zh) | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | 用于肿瘤治疗和预防的致细胞病变病毒 |
| EP1036183B1 (en) | 1997-02-20 | 2007-10-03 | The Johns Hopkins University School Of Medicine | Mutations in atp-dependent transposition proteins that reduce target-site specificity |
| US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
| US20020019051A1 (en) * | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| CN1110553C (zh) | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
| WO2000070071A1 (en) * | 1999-05-17 | 2000-11-23 | Crucell Holland B.V. | Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35 |
| EP1083228A1 (en) * | 1999-09-10 | 2001-03-14 | Introgene B.V. | Modified adenoviral vectors for use in gene therapy |
| US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| EP1301612A2 (en) | 2000-05-31 | 2003-04-16 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| ATE449859T1 (de) * | 2001-01-04 | 2009-12-15 | Goeran Wadell | Virusvektor zur gentherapie |
| AU2003223775A1 (en) | 2002-04-30 | 2003-11-17 | Duke University | Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
| CN1327899C (zh) * | 2003-05-10 | 2007-07-25 | 彭朝晖 | 腺病毒载体与p53基因的基因重组体的应用 |
| NZ551443A (en) | 2004-05-26 | 2010-01-29 | Schering Ag | Chimeric adenoviruses for use in cancer treatment |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| WO2008080003A2 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
-
2005
- 2005-05-24 NZ NZ551443A patent/NZ551443A/en unknown
- 2005-05-24 KR KR1020067027072A patent/KR101169109B1/ko active IP Right Grant
- 2005-05-24 DE DE602005025340T patent/DE602005025340D1/de active Active
- 2005-05-24 CA CA2836987A patent/CA2836987C/en active Active
- 2005-05-24 JP JP2007515285A patent/JP4787936B2/ja active Active
- 2005-05-24 PL PL05753804T patent/PL1749098T3/pl unknown
- 2005-05-24 US US11/136,912 patent/US7510868B2/en active Active
- 2005-05-24 BR BRPI0510475A patent/BRPI0510475B8/pt active IP Right Grant
- 2005-05-24 MX MXPA06013570A patent/MXPA06013570A/es active IP Right Grant
- 2005-05-24 CA CA2567094A patent/CA2567094C/en active Active
- 2005-05-24 CN CN2005800165094A patent/CN1997746B/zh active Active
- 2005-05-24 ES ES05753804T patent/ES2358204T3/es active Active
- 2005-05-24 AU AU2005250396A patent/AU2005250396B2/en active Active
- 2005-05-24 DK DK05753804.3T patent/DK1749098T3/da active
- 2005-05-24 CN CN201310565451.5A patent/CN104263703B9/zh active Active
- 2005-05-24 AT AT05753804T patent/ATE491799T1/de active
- 2005-05-24 RU RU2006145071/10A patent/RU2448157C2/ru active
- 2005-05-24 EP EP05753804A patent/EP1749098B1/en active Active
- 2005-05-24 CN CN201210135656.5A patent/CN102816742B/zh active Active
- 2005-05-24 WO PCT/US2005/018301 patent/WO2005118825A2/en active Application Filing
- 2005-05-24 PT PT05753804T patent/PT1749098E/pt unknown
- 2005-05-24 AR ARP050102135A patent/AR049188A1/es not_active Application Discontinuation
- 2005-05-24 BR BR122013008865A patent/BR122013008865B8/pt active IP Right Grant
- 2005-05-24 UA UAA200613678A patent/UA89957C2/ru unknown
- 2005-05-25 PA PA20058634201A patent/PA8634201A1/es unknown
- 2005-05-25 MY MYPI20052382A patent/MY140829A/en unknown
- 2005-05-25 TW TW094117065A patent/TWI366603B/zh active
- 2005-05-26 PE PE2005000587A patent/PE20060277A1/es active IP Right Grant
- 2005-05-26 UY UY28926A patent/UY28926A1/es active IP Right Grant
- 2005-05-26 GT GT200500129A patent/GT200500129A/es unknown
-
2006
- 2006-11-07 IL IL179098A patent/IL179098A/en active IP Right Grant
- 2006-12-06 CR CR8794A patent/CR8794A/es unknown
- 2006-12-14 EC EC2006007088A patent/ECSP067088A/es unknown
- 2006-12-20 ZA ZA200610763A patent/ZA200610763B/xx unknown
- 2006-12-22 NO NO20066002A patent/NO340708B1/no unknown
-
2007
- 2007-11-26 HK HK07112859.8A patent/HK1109421A1/xx unknown
-
2009
- 2009-03-30 US US12/413,748 patent/US8158599B2/en active Active
-
2011
- 2011-03-11 HR HR20110179T patent/HRP20110179T1/hr unknown
-
2012
- 2012-04-10 US US13/443,055 patent/US8765463B2/en active Active
-
2013
- 2013-03-13 US US13/798,784 patent/US9115337B2/en active Active
- 2013-04-11 AR ARP130101163A patent/AR090647A2/es active IP Right Grant
- 2013-04-15 US US13/862,875 patent/US9034344B2/en active Active
- 2013-06-09 HK HK13106822.6A patent/HK1179655A1/xx unknown
- 2013-06-09 IL IL226820A patent/IL226820A/en active IP Right Grant
-
2014
- 2014-08-20 US US14/464,086 patent/US9234185B2/en active Active
-
2015
- 2015-06-26 HK HK15106084.7A patent/HK1205529A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110179T1 (hr) | Kimerni adenovirusi za uporabu u liječenju raka | |
| RU2361611C2 (ru) | Конструирование рекомбинанта онколитического аденовируса, специфически экспрессирующего иммуномодуляторный фактор gm-csf в опухолевых клетках, и его применение | |
| JP5448840B2 (ja) | 腫瘍退縮アデノウイルスの作出およびその使用 | |
| Yuan et al. | A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9 | |
| Komoto et al. | Generation of infectious recombinant human rotaviruses from just 11 cloned cDNAs encoding the rotavirus genome | |
| WO2020239040A1 (zh) | 重组溶瘤病毒以及制备方法、应用和药物 | |
| CN103352027A (zh) | 肿瘤干细胞的悬浮培养方法 | |
| JP6961788B2 (ja) | プログラム可能な腫瘍溶解性ウイルスワクチン系及びその適用 | |
| BeltCappellino et al. | CRISPR/Cas9-mediated knockout and in situ inversion of the ORF57 gene from all copies of the Kaposi's sarcoma-associated herpesvirus genome in BCBL-1 cells | |
| Léon et al. | The EB66® cell line as a valuable cell substrate for MVA-based vaccines production | |
| CN104212802A (zh) | 一种肿瘤细胞广谱高活性启动子及其用途 | |
| Kimura et al. | Deletion of Viral microRNAs in the Oncogenesis of Epstein–Barr Virus-Associated Lymphoma | |
| CN102533763A (zh) | 慢病毒介导的针对VEGF-C基因siRNA重组体970的构建及用途 | |
| CN102304580A (zh) | 一种筛选猪抗病育种的方法及其应用 | |
| CN101787374A (zh) | 一种基于微小rna调控可在肿瘤细胞内特异性增殖的重组腺病毒载体、其构建方法及其用途 | |
| CN104583410B (zh) | 同时表达猪α干扰素和猪γ干扰素的重组腺病毒 | |
| CN103981185B (zh) | 肝癌特异性gp73核心启动子及其筛选构建方法 | |
| CN112210556A (zh) | 一组靶向干扰IL-33表达的shRNA、重组腺病毒载体及其构建方法和应用 | |
| JPWO2011074564A1 (ja) | アデノウイルスベクターの製造方法 | |
| Tang et al. | In vitro CRISPR-Cas9-mediated efficient Ad5 vector modification | |
| JP2003504316A (ja) | 疾患を処置するためのアデノウイルスベクター | |
| KR20210075126A (ko) | 고도로 콤팩트한 다중-입력 논리 게이트를 코딩하는 핵산 벡터를 사용하여 질환을 치료하는 방법 | |
| TH61714B (th) | ไคเมอริคอะดีโนไวรัสสำหรับใช้ในการรักษามะเร็ง | |
| TH103547A (th) | ไคเมอริคอะดีโนไวรัสสำหรับใช้ในการรักษามะเร็ง | |
| Davola et al. | Genetic modification of oncolytic viruses to enhance antitumor immunity |